Health Day - ONLINE EDITION
Ravicti Approved for Urea Cycle Disorders
Conditions inhibit ammonia removal from the body
FRIDAY, Feb. 1 (HealthDay News) -- Ravicti (glycerol phenylbutyrate) has been approved by the U.S. Food and Drug Administration to treat certain urea cycle disorders (UCDs) in people 2 years and older.
These inherited conditions involve a lack of enzymes that help the body remove ammonia from the blood. In people with UCDs, ammonia buildup can lead to coma, brain damage or death, the FDA said Friday in a news release.
Ravicti is a liquid taken three times daily with meals. It's been approved for people whose disorders cannot be managed by a protein-restricted diet or amino acid supplements alone, the agency said.
Ravicti was compared to another UCD drug in a clinical study involving 44 adults. The most common side effects of the new drug were diarrhea, flatulence and headache.
Ravicti is marketed by Hyperion Therapeutics, based in South San Francisco, Calif.
More information
The U.S. National Library of Medicine has more about UCDs.
More Your Health
- Back to Top
- Return to Your Health
More Your Health
(1 of 7 articles for today)
New Brunswick discouraging new family doctors from practising: medical residents
9:56 AM 0FREDERICTON - A number of doctors in the Maritimes say New Brunswick is discouraging family physicians from practising in the ...
Poll
Ads by Google











You can comment on most stories on winnipegfreepress.com. You can also agree or disagree with other comments. All you need to do is register and/or login and you can join the conversation and give your feedback.
Have Your Say
New to commenting? Check out our Frequently Asked Questions.
The Winnipeg Free Press does not necessarily endorse any of the views posted. By submitting your comment, you agree to our Terms and Conditions. These terms were revised effective April 16, 2010.